IRIS
DEMARZO, MARIA GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 788
Totale 788
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 788
Totale 788
Salva come PNG Salva come JPEG
Città #
Genova 481
Genoa 171
Rapallo 132
Bordighera 4
Totale 788
Salva come PNG Salva come JPEG
Nome #
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 107
Improvement in Waldenstrom’s macroglobulinemia after successful treatment of HCV with direct-acting antivirals 88
Reproducibility and transportability of the absence of incremental infectious adverse events in patients with higher anti-TNF drug levels 79
A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease 76
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 61
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 59
Concerns related to COVID-19 pandemic among patients with Inflammatory Bowel Disease, and its influence on patients management 57
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio 53
Review article – esophageal reflux hypersensitivity: Non-GERD or still GERD? 45
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques 40
Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease 35
Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment 28
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD 27
Pharmacological management of gastro-esophageal reflux disease: An update of the state-of-the-art 22
Letter: predictive factors for treatment discontinuation in IBD—anti-TNF trough levels and anti-drug antibodies 21
An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders 18
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 15
Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission 5
Totale 836
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.235
article - articoli 4.235
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.470
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 0 3 2 2
2019/2020203 2 0 4 33 18 18 23 18 14 41 20 12
2020/2021125 5 15 3 23 6 5 3 22 7 18 8 10
2021/2022184 9 9 5 9 9 20 10 37 17 20 12 27
2022/2023182 24 20 2 5 21 20 5 26 23 1 30 5
2023/2024128 3 19 1 25 19 34 13 1 8 5 0 0
Totale 836